Past, Present, and Future Strategies in the Treatment of High-Grade Glioma in Children

Unlike high-grade glioma in adults, these tumors represent a minority of all primary central nervous system neoplasms in the pediatric age group (< 22 years). Treatment is quite challenging because of the resistance of high-grade glioma in children to radiotherapy and chemotherapy. Whereas maximum resection and radiotherapy are the mainstay of treatment for this type of tumor in children > 3 years, the role of chemotherapy is less clear. Despite the use of multimodality therapy, less than 20 percent of these children are long-term survivors. This review provides an overview of relevant past, current and future treatment strategies for high-grade glioma in children.

[1]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[2]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[3]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[4]  Audrey E. Evans,et al.  The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial , 1989, Journal of Neuro-Oncology.

[5]  P. Burger,et al.  Treatment of infants with malignant gliomas: The Pediatric Oncology Group Experience , 2004, Journal of Neuro-Oncology.

[6]  James M Boyett,et al.  The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. , 2003, Neuro-oncology.

[7]  P D Griffiths,et al.  Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  James M Boyett,et al.  Impact of Proliferation Index on Outcome in Childhood Malignant Gliomas: Results in a Multi-institutional Cohort , 2002, Neurosurgery.

[9]  I. Pollack,et al.  Expression of p53 and prognosis in children with malignant gliomas. , 2002, The New England journal of medicine.

[10]  R. Kortmann,et al.  Preradiation chemotherapy for pediatric patients with high‐grade glioma , 2002, Cancer.

[11]  C. James,et al.  Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Mcgarry,et al.  Chemotherapy response rates in recurrent/progressive pediatric glioma; results of a systematic review. , 1999, Anticancer research.

[14]  R. Sanford,et al.  Supratentorial malignant gliomas in childhood , 1997, Cancer.

[15]  R. Zimmerman,et al.  Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Wisoff,et al.  Survival of infants with malignant astrocytomas. A report from the childrens cancer group , 1995, Cancer.

[17]  S. Bertolone,et al.  Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.